- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05663593
Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers
December 15, 2022 updated by: Haisco Pharmaceutical Group Co., Ltd.
A Randomised, Double-blind, Placebo-controlled, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Oral Doses of HSK31858 in Healthy Volunteers
This is a phase I, randomised, double-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HSK31858 in healthy volunteers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shang Dong
-
Zibo, Shang Dong, China, 255400
- PKUcare Luzhong Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
- Adult males and females, 18 to 45 years of age (inclusive) at Screening.
- Body mass index ≥ 18.0 and ≤ 28.0 kg/m2, with a body weight ≥ 45 kg at Screening.
- Be nonsmokers (including tobacco, e-cigarettes, and marijuana) for at least 1 month prior to first study drug administration.
- Medically healthy without clinically significant abnormalities at Screening and predose on Day 1.
- Conventional 12-lead ECG recording in triplicate (the mean of triplicate measurements will be used to determine eligibility at Screening and predose on Day 1) consistent with normal cardiac conduction and function.
Exclusion Criteria:
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the PI to be clinically relevant.
Subjects has increased risk of infection:
- History and/or presence of tuberculosis (TB).
- Body temperature of > 37.7℃.
- Blood neutrophil count <1.5 × 109/L, or white blood cell count <3.5×109/L (Screening and Day -1).
- Is in high risk-group (i.e., men who have had unprotected sex with men, women who have had sex without a condom with men who have sex with men, people who have had sex without a condom with a person who has lived or travelled in Africa, people who inject drugs, people who have had sex without a condom with somebody who has injected drugs, people who have caught another sexually transmitted infection, people who have received a blood transfusion while in Africa, eastern Europe, the countries of the former Soviet Union, Asia or central and southern America) for human immunodeficiency virus (HIV) infection within the last 6 months.
- Other latent or chronic infections (e.g., recurrent sinusitis, genital or ocular herpes, urinary tract infection) or at risk of infection (surgery, trauma, or significant infection) within 3 months of Screening, or history of skin abscesses within 3 months of Screening.
- Clinically significant lower respiratory tract infection not resolved within 4weeks prior to Screening, as determined by the PI.
- Volunteers with active malignancy or neoplastic disease in the previous 5 years other than superficial basal cell carcinoma.
- Disease history suggesting abnormal immune function or use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 4 months prior to the first study drug administration.
Some subjects lacking functional Dipeptidyl peptidase 1 (DPP1) enzyme have been described to have periodontitis and palmoplantar hyperkeratosis:
- Subjects with signs of current gingivitis/periodontitis. Gingival evaluation (by inspection) will be performed by a dental hygienist or trained study physician.
- Subjects with a history of hyperkeratosis or erythema in palms or soles.
- Liver function test results (i.e., aspartate aminotransferase [AST], alanine aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and total bilirubin elevated more than 1.5 fold above the ULN.
- Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody and human immunodeficiency virus (HIV) antibody test are positive at screening.
- Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- History of alcohol abuse within 12 months prior to first study drug administration or positive alcohol breath test. Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit or a 125 mL glass of wine).
- Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 14 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol. Use of any IP or investigational medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest).
- Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of first study drug administration.
- Participation in another investigational clinical trial within 60 days prior to the first study drug administration.
19. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the Follow-up period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSK31858
Single or multiple oral doses of HSK31858 Tablet, orally once daily
|
Starting dose in single ascending dose: 5 mg
|
Placebo Comparator: Placebo
Matching placebo Tablet, orally once daily
|
Matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number and severity of treatment emergent adverse events (TEAEs)
Time Frame: 7 days after single dose
|
To assess the safety and tolerability of single oral dose of HSK31858 in healthy volunteers
|
7 days after single dose
|
The number and severity of treatment emergent adverse events (TEAEs)
Time Frame: 56 days after multiple dose
|
To assess the safety and tolerability of multiple oral dose of HSK31858 in healthy volunteers
|
56 days after multiple dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: within 30 minutes before administration until 72 hours after administration
|
Maximum concentration
|
within 30 minutes before administration until 72 hours after administration
|
Tmax
Time Frame: within 30 minutes before administration until 72 hours after administration
|
Time to maximum concentration
|
within 30 minutes before administration until 72 hours after administration
|
AUC0-last
Time Frame: within 30 minutes before administration until until 72 hours after administration
|
Area under the drug concentration-time curve, from time 0h to 72h
|
within 30 minutes before administration until until 72 hours after administration
|
t½
Time Frame: within 30 minutes before administration until 72 hours after administration
|
Apparent terminal half-life
|
within 30 minutes before administration until 72 hours after administration
|
Absolute neutrophil count (ANC) normalized relative neutrophil elastase (NE) Activity
Time Frame: within 30 minutes before administration until until 56 days after administration
|
Assessed NE activity changes in multiple doses
|
within 30 minutes before administration until until 56 days after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Hong Wang, Peking University Care Luzhong Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 23, 2022
Primary Completion (Actual)
August 15, 2022
Study Completion (Actual)
November 30, 2022
Study Registration Dates
First Submitted
December 6, 2022
First Submitted That Met QC Criteria
December 15, 2022
First Posted (Actual)
December 23, 2022
Study Record Updates
Last Update Posted (Actual)
December 23, 2022
Last Update Submitted That Met QC Criteria
December 15, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on HSK31858, tablet
-
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical(Australia) Pty Ltd.Completed
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-cystic Fibrosis Bronchiectasis (NCFBE)China
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Sequel Pharmaceuticals, IncTerminatedAtrial Fibrillation
-
Stallergenes GreerCompleted
-
TakedaWithdrawn
-
Harmony Biosciences, LLCRecruiting
-
Xgene Pharmaceutical GroupRecruiting
-
Abbisko Therapeutics Co, LtdCompleted